leadf
logo-loader
viewMedexus Pharmaceuticals Inc
(
TSX-V:MDPOTCQX:MEDXF
)

Medexus Pharmaceuticals reveals 4Q revenue surge

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive its fourth quarterly revenue doubled year-over-year thanks in large part to its February acquisition of Aptevo BioTherapeutics LLC.

d’Entremont says the pharmaceutical company posted revenue of C$25.6 million in the three months ended March 31, compared to C$12.7 million in the same period a year earlier. Gross profit for the quarter jumped to C$13.3 million from C$7.7 million, and net loss increased to C$2.1 million from C$700,000.

Quick facts: Medexus Pharmaceuticals Inc

Follow
TSX-V:MDP

Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals reveals record quarterly revenue of C$31.5M

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive its fiscal third quarter results revealed record quarterly revenue of C$31.5M, nearly doubling its revenue year-over-year from C$16.2M in the same period in 2019. d’Entremont added given significant share...

on 03/02/2021

2 min read